Antibiotics

Prof. James Collins and his colleagues are using AI to develop new antibiotic compounds to treat infections and combat antibiotic resistance concerns, reports Lisa M. Krieger for the San Fransico Chronicle. “Looking at the structure of a compound — bond by bond, substructure by substructure — it (AI) can make a calculation of the probability that it could be antibacterial,” explains Collins. So far, “Collins and his colleagues have synthesized several compounds that combat hard-to-treat infections of gonorrhea and MRSA,” writes Krieger. “These techniques are also being harnessed to fight diseases, like cancer, lupus and arthritis.” 

Prof. James Collins speaks with Financial Times reporter Patrick Temple-West about his work using AI to design new antibiotic compounds to combat drug-resistant bacteria. “At present, the [AI] models are doing quite well at designing compounds that can attack in a Petri dish,” says Collins. 

Researchers at MIT are using AI systems to design new molecules for potential antibiotics, research that is “aimed at the growing challenge of antibiotic-resistant infections,” reports Adele Peters for Fast Company. “The number of resistant bacterial pathogens has been growing, decade upon decade,” says Prof. James Collins. “And the number of new antibiotics being developed has been dropping, decade upon decade.” 

Using AI, researchers at MIT have developed new antibiotics for gonorrhoea and MRSA, two infections that are typically hard to treat. The team “trained the AI to help it learn how bacteria was affected by different molecular structures built of atoms in order to design new antibiotics,” writes Ruth Stainer for the Daily Mail. “[A]nything too similar to the current antibiotics available, or with the potential to be toxic to human beings, was eradicated.” 

Researchers at MIT used AI to “design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA,” reports ITV News. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,” says Prof. James Collins. 

Using generative AI, researchers at MT have designed new antibiotics to combat MRSA and gonorrhea, reports James Gallagher for the BBC. "We're excited because we show that generative AI can be used to design completely new antibiotics," says Prof. James Collins. "AI can enable us to come up with molecules, cheaply and quickly and in this way, expand our arsenal, and really give us a leg up in the battle of our wits against the genes of superbugs."

Wall Street Journal reporter Dominique Mosbergen spotlights how Prof. James Collins and his lab have built their “own algorithms to trawl chemical databases, such as those of existing pharmaceutical drugs, for potential antibacterial compounds.” Collins’ His lab is “also experimenting with using generative AI to design completely new molecules that could kill bacteria,” writes Mosbergen. 

MIT researchers have discovered “a new way to interfere with a certain bacterial enzyme that may lead to a new class of antibiotics,” reports Meryl Davids Landau for National Geographic. 

Prof. Regina Barzilay joins The Economist’s “Babbage” podcast to discuss how artificial intelligence could enable health care providers to understand and treat diseases in new ways. Host Alok Jha notes that Barzilay is determined to “overcome those challenges that are standing in the way of getting AI models to become useful in health care.” Barzilay explains: “I think we really need to change our mindset and think how we can solve the many problems for which human experts were unable to find a way forward.”  

In a new paper, MIT researchers detail how they have used AI techniques to discover a class of “of antibiotics capable of killing methicillin-resistant Staphylococcus aureus (MRSA),” reports Helen Floresh for Fierce Biotech. “This paper announces the first AI-driven discovery of a new class of small molecule antibiotics capable of addressing antibiotic resistance, and one of the few to have been discovered overall in the past 60 years,” says postdoctoral fellow Felix Wong.

Researchers at MIT have used artificial intelligence to uncover, “a new class of antibiotics that can treat infections caused by drug-resistant bacteria,” reports Jeremy Hsu for New Scientist. “Our [AI] models tell us not only which compounds have selective antibiotic activity, but also why, in terms of their chemical structure,” says postdoctoral fellow Felix Wong.

Researchers at MIT and elsewhere have used artificial intelligence to develop a new antibiotic to combat Acinetobacter baumannii, a challenging bacteria known to become resistant to antibiotics, reports Hannah Kuchler for the Financial Times. “It took just an hour and a half — a long lunch — for the AI to serve up a potential new antibiotic, an offering to a world contending with the rise of so-called superbugs: bacteria, viruses, fungi and parasites that have mutated and no longer respond to the drugs we have available,” writes Kuchler.

Researchers from MIT and McMaster University have used artificial intelligence to identify a new antibiotic that can fight against a drug-resistant bacteria commonly found in hospitals and medical offices, reports Ken Alltucker for USA Today. The researchers believe the AI “process used to winnow thousands of potential drugs to identify one that may work is an approach that can work in drug discovery,” writes Alltucker.

Researchers from MIT and elsewhere have used artificial intelligence to develop a new antibiotic to address Acinetobacter baumannii, a bacteria known for infecting wounds, lungs and kidneys, reports Harland-Dunaway for The World.

Using a machine-learning algorithm, researchers from MIT and McMaster University have discovered a new type of antibiotic that works against a type of drug-resistant bacteria, reports Brenda Goodman for CNN. Goodman notes that the compound “worked in a way that stymied only the problem pathogen. It didn’t seem to kill the many other species of beneficial bacteria that live in the gut or on the skin, making it a rare narrowly targeted agent.”